Gene Logic Launches ToxShield Suite to Enable Customers to Conduct Pre

Gene Logic Launches ToxShield Suite to Enable Customers to Conduct Predictive Toxicogenomic Characterizations of Drug Compounds In-House

    Business Editors/Health Editors/Medical Editors
    BIOWIRE2K

    GAITHERSBURG, Md.--(BUSINESS WIRE)--Feb. 22, 2005--

New Web-Based Platform Offers Toxicologists and Drug Safety Scientists
    Direct Access to Proven Predictive Toxicogenomic Capabilities

    Gene Logic Inc. (NASDAQ:GLGC) today launched ToxShield(TM) Suite 1.0, a Web-enabled software platform for assessing and rank ordering candidate drug compounds based on potential toxicities in humans. Toxicologists and drug safety scientists at global pharmaceutical companies will use ToxShield Suite and the reports generated to enhance their compound development decision-making processes.
    Gene Logic's expertise in microarray data generation, predictive toxicogenomic analyses, and assessment of a broad range of customer's live compounds, failed drugs and reference compounds has facilitated the discovery and validation of accurate markers of toxicity. ToxShield Suite draws from these predictive toxicogenomics efforts and is validated by more than 350 predictive toxicity assessments on a variety of compounds across multiple organ systems and primary rat hepatocytes.
    Over the past three years, pharmaceutical clients have requested that Gene Logic conduct toxicity assessments on their proprietary compounds at a growing rate. With the launch of ToxShield Suite, Gene Logic has achieved a technology transfer breakthrough - enabling biotechnology and pharmaceutical companies to conduct these toxicity assessments on site.
    Using ToxShield Suite, researchers can rapidly analyze the gene expression data resulting from assessment of their proprietary compounds directly from their desktops. Each resulting ToxShield Suite report characterizes proprietary candidate compounds for predicted toxicity, proposes likely-induced pathologies, and finds reference compound matches from those residing in the ToxExpress(R) System.

    ToxShield Suite enables toxicologists to:

--	Rank candidate leads within and between compound series using toxicity assessments provided by validated predictive models.
--	Expand their internal knowledge base of toxicogenomic marker response across diverse compounds.
--	Develop screening assays for related compounds or chemical series based on Gene Logic's toxicity markers.

    ToxShield Suite also addresses difficult research questions such as:

    -- Is the compound likely to be a human toxicant?

    -- What type of injury will it likely induce in humans or rats?

    -- What reference compounds does it most closely resemble at the
    level of gene expression?

    -- Is there a time and dose relationship with this compound at
    the level of gene expression?

    Dennis A. Rossi, Senior Vice President and General Manager for Genomics at Gene Logic, commented, "ToxShield Suite addresses the industry's growing need for a rapid and robust solution for toxicogenomics-based evaluation of candidate compounds' potential for human toxicity. In the hands of pharma researchers, ToxShield and its automated reports can increase industry productivity by establishing a mechanism to test candidate compounds much earlier in the discovery phase."
    The Company will showcase the technical specifications and benefits of ToxShield Suite at the Society of Toxicology Annual Meeting for 2005, held in New Orleans, March 6-10, 2005.
    Additional information about ToxShield Suite is available at www.genelogic.com.

    Gene Logic Overview

    Gene Logic aspires to be a valued outsourcing partner for the pharmaceutical industry. As a leading drug development services provider, Gene Logic applies its broad and unique mix of technologies, talent and methodologies to work on behalf of its partners to enable them to make more informed, more reliable and more predictive decisions at each point in the highly complex and costly drug development process. For more information, visit www.genelogic.com or call toll-free - 1/800/GENELOGIC.

--30--TG/ph*

CONTACT: Gene Logic Inc. Investors/Media: Robert G. Burrows, 301-987-1824 Email: rburrows@genelogic.com

KEYWORD: MARYLAND INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL MEDICAL DEVICES BIOTECHNOLOGY SOFTWARE PRODUCT SOURCE: Gene Logic Inc.

Copyright Business Wire 2005